Hologic Inc. (NASDAQ:HOLX) has earned a consensus rating of “Buy” from the nineteen brokerages that are currently covering the stock. Six equities research analysts have rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $42.60.
Several equities research analysts have recently issued reports on the stock. Piper Jaffray Cos. set a $44.00 price objective on shares of Hologic and gave the stock a “hold” rating in a research note on Sunday, August 28th. Needham & Company LLC reiterated a “hold” rating on shares of Hologic in a research note on Thursday, July 28th. BTIG Research reiterated a “buy” rating and set a $44.00 price target on shares of Hologic in a research note on Thursday, July 28th. Jefferies Group lifted their price target on shares of Hologic from $42.00 to $43.00 and gave the stock a “buy” rating in a research note on Thursday, July 28th. Finally, Morgan Stanley lifted their price target on shares of Hologic from $38.00 to $40.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 28th.
In related news, Director Nancy Leaming sold 8,179 shares of Hologic stock in a transaction dated Thursday, July 21st. The stock was sold at an average price of $37.00, for a total value of $302,623.00. Following the completion of the transaction, the director now directly owns 67,140 shares of the company’s stock, valued at $2,484,180. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.84% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in HOLX. Fairpointe Capital LLC boosted its position in Hologic by 40.3% in the first quarter. Fairpointe Capital LLC now owns 20,900 shares of the company’s stock worth $721,000 after buying an additional 6,000 shares in the last quarter. Cleararc Capital Inc. acquired a new position in Hologic during the first quarter worth about $213,000. Quadrature Capital Ltd acquired a new position in Hologic during the first quarter worth about $2,704,000. UBS Asset Management Americas Inc. boosted its position in Hologic by 1.2% in the first quarter. UBS Asset Management Americas Inc. now owns 637,813 shares of the company’s stock worth $22,006,000 after buying an additional 7,810 shares in the last quarter. Finally, UBS Group AG boosted its position in Hologic by 5.8% in the first quarter. UBS Group AG now owns 794,751 shares of the company’s stock worth $27,419,000 after buying an additional 43,652 shares in the last quarter. 94.51% of the stock is owned by institutional investors and hedge funds.
Hologic (NASDAQ:HOLX) opened at 39.74 on Wednesday. The company has a market cap of $11.02 billion, a price-to-earnings ratio of 43.81 and a beta of 1.00. The company has a 50-day moving average of $38.44 and a 200-day moving average of $36.22. Hologic has a 12 month low of $31.84 and a 12 month high of $41.66.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, July 27th. The company reported $0.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.03. The business had revenue of $717.40 million for the quarter, compared to the consensus estimate of $703.66 million. Hologic had a net margin of 9.39% and a return on equity of 26.25%. Hologic’s quarterly revenue was up 3.4% on a year-over-year basis. During the same quarter last year, the company posted $0.43 earnings per share. Analysts predict that Hologic will post $1.94 EPS for the current year.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.